


Immune Interference in *Mycobacterium tuberculosis* Intracellular Iron Acquisition through Siderocalin Recognition of CarboxymycobactinsTrisha M. Hoette,^{†,§,⊥} Matthew C. Clifton,^{‡,||,⊥} Anna M. Zawadzka,[†] Meg A. Holmes,[‡] Roland K. Strong,^{‡,*} and Kenneth N. Raymond^{†,*}[†]Department of Chemistry, University of California, Berkeley, California 94720-1460, United States[‡]Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States

S Supporting Information

ABSTRACT: The innate immune system antibacterial protein Siderocalin (Scn) binds ferric carboxymycobactin (CMB) and also several catecholate siderophores. Although the recognition of catecholates by Scn has been thoroughly investigated, the binding interactions of Scn with the full spectrum of CMB isoforms have not been studied. Here we show that Scn uses different binding modes for the limited subset of bound CMB isoforms, resulting in a range of binding affinities that are much weaker than other siderophore targets of Scn. Understanding the binding interaction between Scn and CMBs provides clues for the influence of Scn on mycobacterial iron acquisition.



From microbes to mammals, iron is essential for virtually all living organisms. Therefore, an organism that can efficiently acquire, utilize, and store iron may out-compete other organisms for survival.¹ While iron is sequestered in the human body by intracellular ferritin and extracellular transferrin,² during an infection bacterial pathogens can employ siderophores (high-affinity, small-molecule chelators) with sufficient strength to remove ferric ions from the host's iron stores.³ Siderocalin (Scn; aka Lcn2, Ngal, and 24p3) is a mammalian antibacterial protein that acts as a second line of defense against iron piracy by binding siderophores and their ferric complexes, thereby intercepting the delivery of iron to the bacteria.⁴ The human pathogen *Mycobacterium tuberculosis* (*Mtb*), the causative agent of tuberculosis, localizes inside host macrophages during infection⁵ and taps into intracellular iron stores for survival.⁶ Recent literature has shown that Scn suppresses the *in vitro* growth of mycobacteria,^{7–9} and although this influence is attributed to Scn interfering with siderophore-mediated iron acquisition, this mechanism of action has yet to be fully elucidated.

The “stealth” siderophore phenomenon has been described in the siderophore systems of a number of human pathogens. For example, while Gram-positive pathogens *Bacillus anthracis* and *Bacillus cereus* produce both bacillibactin (BB) and petrobactin (PB),^{10,11} only PB is not sequestered by Scn¹² and, as a result, is a virulence factor for the pathogen. Similarly, pathogenic strains of Gram-negative enteric bacteria, such as *Salmonella enterica* and *typhimurium* and *Escherichia coli*, produce both enterobactin (Ent) and its glycosylated derivative, salmochelin (S4), and only S4 confers virulence in the presence of the innate immune response due to its ability to evade Scn.¹³ The use of a stealth siderophore under the pressure of the Scn immune response is one advantage of using a diverse, multi-siderophore iron acquisition system by pathogenic bacteria.

Mtb is an unusually persistent bacterium that is able to survive a number of environmental stresses including desiccation,

osmotic shock, and nutrient deprivation.¹⁴ Nonetheless, survival is still dependent on the ability of the pathogen to acquire iron.¹⁵ Carboxymycobactins (CMBs, Figure 1) are a suite of siderophores differing in the length of the fatty acid tail ($n = 3–10$) produced by *Mtb* to sequester iron from within the host macrophage.¹⁶ (Other siderophores produced include the structurally similar, cell-associated mycobactins and the hydroxamate-based exochelins.¹⁷)

In 2005, the crystal structure of Scn bound to Fe^{III} CMB provided the first indication that the Scn immune response may impede the pathogenicity of *Mtb* by interfering with its iron acquisition.¹⁸ Although Scn was in the crystallization solution with a mixture of ferric CMBs, only the $n = 6$ isoform was bound within the protein calyx in the crystal structure. This observation raised several new questions about the influence of Scn on iron acquisition in *Mtb*. Does Scn also bind the ferric complexes of the other CMB isoforms? Does Scn selectively bind the $n = 6$ isoform over the others? What is the binding affinity of Scn for the CMBs? How does the Scn– Fe^{III} CMB interaction compare to the Scn binding interactions with other siderophores? And ultimately, how does the presence of Scn in the host versus the secretion of a suite of siderophores by the pathogen affect the balance of iron during an *Mtb* infection?

To begin to answer these questions about the functional significance of the *Mtb* suite of siderophores, a mixture of CMBs was isolated from the nonpathogenic bacterium *M. smegmatis*,¹⁹ and the individual ferric complex isoforms ($n = 3–8$) were separated by HPLC (Supplementary Figure 1). CMBs of longer tail length were also detectable in the mixture, although in trace amounts. The separated compounds were characterized by

Received: August 31, 2011

Accepted: October 6, 2011

Published: October 06, 2011





Figure 1. Molecular structure of carboxymycobactin (CMB, left, where $n = 3-10$ in the fatty acid tail). CMB is a hexadentate ligand that forms a mononuclear ferric complex with iron (1:1 Fe:CMB). Iron binding atoms shown in red. To the right, fluorescence binding analysis of Scn ($0.1 \mu\text{M}$) with Fe^{III} CMB isoforms ($n = 3-8$) at pH 7.4. Symbols indicate fluorescence data at 340 nm, and lines are calculated nonlinear least-squares fits (DYNAFIT²⁵).

Table 1. Dissociation Constants Determined by Fluorescence for Scn Binding to CMB Isoforms ($n = 3-8$)^a

Fe^{III} CMB (by n)	K_d (μM)	est SD
3	>9	
4	2.36	$\pm 9.0 \times 10^{-3}$
5	1.10	$\pm 2.6 \times 10^{-2}$
6	0.654	$\pm 2.2 \times 10^{-2}$
7	0.128	$\pm 1.0 \times 10^{-3}$
8	0.280	nd ^b

^aUncertainties were determined from the standard deviation of three independent titrations. ^bMinimal sample size allowed for only one binding experiment.

LC-MS and UV-vis spectroscopy ($\lambda_{\text{max}} = 450 \text{ nm}$, $\epsilon = 3,800 \text{ M}^{-1} \text{ cm}^{-1}$; based on the reported $A^{1\%}$, *i.e.*, the absorbance of a 1% solution of CMBs)¹⁹⁻²¹ to ensure that each isoform had been completely separated from the others in the suite. Subsequently, the interaction of each isoform with Scn was analyzed through fluorescence binding assays and protein crystallography.

The fluorescence methods used in Scn binding studies for all previous siderophore systems were employed for the ferric CMBs.^{4,12,22} The range of binding constants determined for the suite of siderophores spans over 2 orders of magnitude in affinity. The strongest binding ferric CMB complex is the $n = 7$ Fe^{III} CMB ($K_d = 128 \text{ nM}$), and the affinity for the other isoforms decreases in both directions of the series such that the dissociation constants for n are in the order $7 < 8 < 6 < 5 < 4 < 3$ (Figure 1 and Table 1). In general, Scn binds Fe^{III} CMB with lower affinity (nearly 1000-fold weaker for even the tightest binder) than previously described ferric siderophore substrates BB¹² and Ent.⁴

Next, the individual isoforms were co-crystallized with Scn in order to correlate the variable dissociation constants with the molecular interactions within the protein calyx. Although crystals were obtained for all isolable isoforms ($n = 3-8$, Supplementary Figure 2), the electron density was interpretable only for CMBs with tail lengths $n = 5$ (Fe^{III} CMB-5), $n = 6$ (Fe^{III} CMB-6, the original structure¹⁸), and $n = 7$ (Fe^{III} CMB-7). The structures of these three isoforms are shown in Figure 2. Crystallographic analysis of the Fe^{III} CMBs bound to wild type human Scn show that the change in the tail length of CMB does not affect the backbone conformation of Scn locally or globally (superpositions




Figure 2. Structures of Scn bound to Fe^{III} CMB. The carboxylate tail is found bound in the lower portion of pocket 2 in both the $n = 6$ (Fe^{III} CMB-6, middle) and $n = 7$ (Fe^{III} CMB-7, bottom) structures. In contrast, the tail adapts both a “tail in” and “tail out” conformation in the case of $n = 5$ (Fe^{III} CMB-5, top). To accommodate the “tail in” binding conformation, the hydroxamate in pocket 3 shifts 2.0 \AA down into the calyx, disrupting ideal iron coordination.

rmcs of Fe^{III} CMB-5 onto the original Fe^{III} CMB-6 structure (PDB accession code 1X89): 0.12 \AA molecule A, 0.17 \AA molecule B, and 0.12 \AA molecule C; superpositions rmcs of Fe^{III} CMB-5 onto the original Fe^{III} CMB-6 structure: 0.19 \AA molecule A, 0.30 \AA molecule B, and 0.20 \AA molecule C; calculated on all common C α). There were no significant changes between the original Fe^{III} CMB $n = 6$ structure and the $n = 5$ and $n = 7$ structures with

the exception of the position of the bound siderophore within the calyx. Three pockets in the Scn calyx are walled off from each other by side chains with pocket 1 defined by the side chains of Lys125 and Lys134, pocket 2 defined by Lys134 and Trp79/Arg81, and pocket 3 defined by Trp79/Arg81 and Lys125. Previous studies have shown that the cationic calyx residues (Lys125, Lys134, Arg81) play an important role in the recognition of siderophores through electrostatic interactions.^{4,22} Similar to the original structure, the hydroxyphenyl oxazoline (HPO) group is bound in pocket 1 between Lys125 and Lys134, and the seven-membered cyclic hydroxamate in pocket 2 between Lys134 and Arg81. The fatty acid tail branches from the hydroxamate bound in pocket 3 and reaches down into a subpocket located below pocket 2.

The fatty acid tail of Fe^{III}CMB-5 is found in two different conformations: “tail in”, where the tail of CMB binds deep into pocket 2, and “tail out” where the tail of CMB moves out the backside of pocket 3 and away from the calyx. Conversely, the structure of Fe^{III}CMB-7 has the same siderophore binding mode as the previously published Fe^{III}CMB-6 in which the tail is tucked under the complex and the carboxylate is buried deep in pocket 2. While the electron density is difficult to interpret in the Fe^{III}CMB $n = 4$ structure, it is apparent that the tail is not seen buried deep in pocket 2, likely contributing to the overall disorder of the siderophore in these data sets. There was no density for the siderophore found in the Fe^{III}CMB $n = 3$ structure.

There is a correlation between the affinities determined by fluorescence and the binding modes determined by crystallography. The two binding modes of the CMBs, “tail in” and “tail out”, show that the tucked tail creates an important interaction in the recognition of Fe^{III}CMB. It has been previously observed that the positioning of the tail in the pocket mirrors the crystal structure of Scn bound to an opportunistic ligand, *n*-capric acid.¹⁸ In this structure, the carboxylate of the fatty acid was bound in pocket 2 with the alkyl tail trailing into the calyx.²³ Without this interaction, the mechanism of recognition of the Fe^{III}CMB substrate is severely hindered. We speculate that the smaller tail lengths are not long enough to tuck under the complex and bury the carboxylate and, as a result, are bound with lower affinity by Scn.

The molecular structure of CMB is vastly different from catecholate siderophores (BB, Ent, parabactin, *etc.*) yet it is still bound by Scn, emphasizing the effectiveness of the generalized recognition strategy of Scn based on hybrid electrostatic interactions (cation- π with aromatic metal-binding units and Coulombic with anionic complexes).^{4,22} CMB has only a single aromatic unit, the HPO, to participate in a cation- π binding interaction within the Scn calyx, compared to the tris-catecholate Scn substrates Ent and BB. The position of the HPO unit in the CMB-Scn co-crystal structures in between the Lys125 and Lys134 in pocket 1 is conserved across all the structures, and the phenol ring of the HPO superimposes with the catecholamide of Ent from the Scn co-crystal (Supplementary Figure 4). The electrostatic potential map of the HPO binding unit (Figure 3), along with the calculated cation-binding energies ($BE_{\text{apoHPO}} = 22.51$ kcal/mol, $BE_{\text{M-HPO}} = 36.68$ kcal/mol), demonstrate an enhanced ability to participate in a cation- π interaction compared to the 2,3-catecholamide.²³

Several tris-hydroxamate siderophores have been demonstrated to not bind to Scn.¹⁸ The lack of recognition is attributed to (a) the absence of aromatic binding units, which negates the cation- π binding interaction; (b) the formation of neutral ferric complexes, which negates the Coulombic binding interaction;




Figure 3. Electrostatic potentials for HPO and M-HPO units (with the input structures) were calculated at the RHF/6-311G** level of theory with iso-values of -0.2 (red) to 0.2 (blue). Cation- π interaction energies were calculated at the MP2/6-311G** level of theory, and BSSE was corrected for with the counterpoise method.

and (c) the lack of shape complementarity with Scn. Despite the neutral, bishydroxamate iron coordination of CMB, some isoforms are still sequestered by Scn. The HPO unit enables Scn to recognize the primary coordination sphere of the complex through enhanced cation- π interactions. Furthermore, the fatty acid tail is the source of the overall monoanionic complex charge. However, CMB complexes that cannot adopt the “tail-in” conformation in the Scn calyx eliminate the Coulombic binding interaction. Therefore, while the HPO unit is critical to the Scn recognition of CMB, the length of the fatty acid tail ultimately determines whether a CMB complex is intercepted by Scn.

In addition to Scn dissociation constant, another important factor in siderophore sequestration is the rate at which the siderophore dissociates from Scn. In other words, the half-life of the protein complex ultimately determines the effectiveness of the sequestration. While the siderophore off-rate was not determined in this study, the variance binding mode among the CMBs with a corresponding change in dissociation constants suggest that varying tail lengths in the suite of CMBs is the means of immunoevasion. Moreover, the relatively weak binding affinities indicate that the function of these siderophores is more complex than simply acting as stealth siderophores. Although the dissociation constant of the *Mtb* receptor for Fe^{III}CMB has not been reported, the weak affinity of Scn for the Fe^{III}CMBs may indicate that Scn cannot interrupt iron transport in *Mtb* in the same way as the Ent and BB bacterial systems. This is corroborated by Halaas *et al.*, who showed that inhibiting the synthetic pathway of the CMBs with *p*-aminosalicylate was more effective at growth inhibition of mycobacteria *in vitro* than Scn.⁹

Because *Mtb* is primarily an intracellular bacterium, the host-pathogen interactions are more pronounced. As a result, *Mtb* has developed more complex survival strategies than the typical extracellular bacteria. One example of this is the mechanism by which *Mtb* evades cell death by preventing fusion with late endocytic organelles in the macrophage.^{14,17} Similarly, in order to overcome host defenses, the siderophore production of *Mtb* must be tailored specifically to acquire iron from within the host cell. Recent *in vivo* studies have shown that Scn is most effective against free-living *M. avium* in the bloodstream during the early phase of infection, where a substantial fraction of the bacteria are extracellular, but is less effective at suppressing the growth of intracellular mycobacteria.⁹ This is attributed to the fact that within macrophages Scn is eventually trafficked to endolysosomes, whereas the pathogen colocalizes with intracellular transferrin in separate compartments. While the intracellular iron acquisition of *Mtb* is not yet well understood, the atypical structures of CMB and mycobactin, including the cyclic hydroxamate, the HPO, and the side chains, are a testament to the strides the bacterium takes to produce a siderophore uniquely qualified for this task. One example

of the structure–function correlation in these siderophores is the wide range of lipophilicities of CMBs and mycobactins, which enable the siderophores to navigate throughout the cell in search of iron stores.²⁴ Although CMB is captured by Scn in some cases, the ultimate survival of the pathogen implies that the Scn immune response does not effectively inhibit iron acquisition by mycobacteria.

METHODS

General. The Fe^{III}CMBs were isolated from *M. smegmatis* using published procedures.^{19,21} *M. smegmatis* strain mc² 155 was obtained from Prof. Hiroshi Nikaido (University of California, Berkeley). Affinities of Scn for the CMBs were determined by a fluorescence-based binding assay as previously described.⁴ Electrostatic calculations were performed according to published procedures.^{23,26} Computational studies were conducted at the Molecular Graphics and Computation Facility, College of Chemistry, University of California, Berkeley.

HPLC Conditions. Separation of the ferric CMBs was achieved on an Agilent Eclipse XDB-C18 (reverse phase) 5 μ M semipreparative column with a gradient solvent system of water/methanol (50:50 at 0 min to 30:70 at 30 min) with a flow rate of 1.25 mL/min and a detection wavelength of 450 nm. The 30:70 system was maintained for an additional 50 min while the Fe^{III}CMB fractions eluted. The fractions were analyzed by LC–MS to identify the isoform (Supplementary Figure S1) and condensed, and a second HPLC run was performed with the same water/methanol solvent system to further purify the complexes (with UV–vis detection at 450, 310, and 254 nm). The fractions were dried, and pure ferric CMBs were stored under vacuum in a dark cabinet until it was used in binding studies (usually within 3 days).

LC–MS Characterization. Ferric CMB-containing HPLC fractions were analyzed by LC–MS on an Agilent Eclipse XDB-C18 (reverse phase) 5 μ M analytical column ($\lambda = 450$ nm, flow rate = 0.5 mL/min) with the following gradient: 0 min, 50:50 (H₂O/MeOH); 10 min, 30:70 (H₂O/MeOH); 30 min, 30:70 (H₂O/MeOH); 33 min 50:50 (H₂O/MeOH).

Fluorescence Quenching Binding Assay. Fluorescence quenching of recombinant Scn was measured on a Cary Eclipse fluorescence spectrophotometer. A 5 nm slit band-pass for excitation and a 10 nm slit band-pass for emission were used with a high-voltage detector. An excitation wavelength of $\lambda_{\text{exc}} = 281$ nm was used, and emission was collected at $\lambda_{\text{em}} = 340$ nm. Measurements were made at a protein concentration of 100 nM in buffered aqueous solutions, plus 32 μ g/mL ubiquitin (Sigma) and 5% DMSO. Fluorescence values were corrected for dilution upon addition of substrate. Fluorescence data were analyzed by nonlinear regression analysis of fluorescence response versus substrate concentration using a one-site binding model as implemented in DYNAFIT.²⁵ All standard binding experiments were done at pH 7.4 using TBS aqueous buffer. Control experiments were performed to ensure the stability of the protein at experimental conditions, including dilution and the addition of ubiquitin and DMSO.

Computational Methods. To determine the quadrupole moments, Θ_{zz} , the aromatic structures were geometry optimized and characterized *via* frequency calculations at the RHF/6-311G** level of theory in the Gaussian 03 package.²⁶ To determine the aromatic-cation interaction energies the aromatic structures, the sodium cation, and the aromatic-cation complexes were characterized *via* a frequency calculation at the MP2/6-311++G** level of theory, and the aromatic-cation interaction energies were corrected for basis set superposition error (BSSE) with the counterpoise method in the Gaussian 03 package.²⁶ In the aromatic-cation calculations the sodium ion was fixed at a distance of 2.47 Å above the centroid of the aromatic unit. To determine the orbitals involved in the ES IPT and the triplet energy for the HPO unit, time-dependent density functional theory calculations were performed using a B3LYP/6-311++G(d,p) basis set in Gaussian 03 package.²⁶ Geometry

optimizations were performed on the input structures without symmetry constraints.

Protein Crystallographic Studies. Human Scn was isomorphously co-crystallized with Fe^{III}CMB with fatty acid tail lengths $n = 3, 4, 5, 6, 7,$ and 8 using the previously reported crystallization conditions¹⁸ Crystals were cryoprotected by supplementing the mother liquor with 15% glycerol before flash freezing them in liquid nitrogen at -170 °C. All data sets were collected at the Advanced Light Source in Berkeley, CA and processed with the HKL2000 software package.²⁷ Reflections chosen for calculating R_{free} were matched to those used in the original wild type human structure (PDB code 1L6M). Phases were calculated using the original Scn structure, modeling was performed with Coot, and the structure was refined using Refmac5.^{28–30} Relevant data collection and refinement statistics are shown in Table 1. Coordinates for both structures have been deposited with the PDB (accession codes 3PEC and 3PED).

ASSOCIATED CONTENT

Supporting Information. This material is available free of charge *via* the Internet at <http://pubs.acs.org>

AUTHOR INFORMATION

Corresponding Author

*E-mail: raymond@socrates.berkeley.edu; rstorng@fhcrc.org.

Present Addresses

[§]Sandia National Laboratories, 7011 East Ave., Livermore, CA 94550.

^{||}Emerald BioStructures, 7869 NE Day Road West, Bainbridge Island, WA 98110.

Author Contributions

[†]These authors contributed equally to this work.

ACKNOWLEDGMENT

This work was supported by the National Institutes of Health (Grants R01AI11744 and R01AI59432). The authors thank the Advanced Light Source beamline 5.0.1 for crystallographic data collection, H. Nikaido for the *M. smegmatis* strain, C. Chang for use of his LC–MS, and R. Abergel for helpful discussions. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231.

REFERENCES

- (1) Miethke, M., and Marahiel, M. A. (2007) Siderophore-based iron acquisition and pathogen control. *Microbiol. Mol. Biol. Rev.* 71, 413–451.
- (2) Weinberg, E. D. (1999) Iron loading and disease surveillance. *Emerging Infect. Dis.* 5, 346–352.
- (3) Raymond, K. N., Dertz, E. A. (2004) Biochemical and physical properties of siderophores, in *Iron Transport in Bacteria* (Crosa, J. H., Mey, A. R., and Payne, S. M., Eds.) pp 3–17, ASM Press, Washington, DC.
- (4) Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., and Strong, R. K. (2002) The neutrophil Lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Mol. Cell* 10, 1033–1043.
- (5) Kauffmann, S. H. E. (2004) New issues in tuberculosis. *Ann. Rheum. Dis.* 63, 1150–1156.
- (6) Olakanmi, O., Schlesinger, L. S., and Britigan, B. E. (2007) Hereditary hemochromatosis results in decreased iron acquisition and

growth by *Mycobacterium tuberculosis* within human macrophages. *J. Leuk. Biol.* 81, 195–204.

(7) Saiga, H., Nishimura, J., Kuwata, H., Okuyama, M., Matsumoto, S., Sato, S., Matsumoto, M., Akira, S., Yoshikai, Y., Honda, K., Yamamoto, M., and Takeda, K. (2008) Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. *J. Immunol.* 181, 8521–8527.

(8) Martineau, A. R., Newton, S. M., Wilkinson, K. A., Kampmann, B., Hall, B. M., Nawroly, N., Packe, G. E., Davidson, R. N., Groffiths, C. J., and Wilkinson, R. J. (2007) Neutrophil-mediated innate immune resistance to mycobacteria. *J. Clin. Inv.* 117, 1988–1994.

(9) Halaas, Ø., Steigedal, M., Haug, M., Awuh, J., Ryan, L., Brech, A., Sato, S., Husebye, H., Cangelosi, G. A., Akira, S., Strong, R. K., Espevik, T., and Flo, T. H. (2010) Intracellular *Mycobacterium avium* intersect transferrin in the Rab11⁺ recycling endocytic pathway and avoid Lipocalin 2 trafficking the lysosomal pathway. *J. Infect. Dis.* 201, 783–792.

(10) Wilson, M. K., Abergel, R. J., Raymond, K. N., Arceneau, J. E. L., and Byers, B. R. (2006) Siderophores of *Bacillus anthracis*, *Bacillus cereus*, and *Bacillus thuringiensis*. *Biochem. Biophys. Res. Commun.* 348, 320–325.

(11) Koppisch, A. T., Browder, C. C., Moe, A. M., Shelley, J. T., Kinkel, B. A., Hersman, L. E., Iyer, S., and Ruggiero, C. E. (2005) Petrobactin is the primary siderophore synthesized by *Bacillus anthracis* Str. Sterne under conditions of iron starvation. *BioMetals* 18, 577–585.

(12) Abergel, R. J., Wilson, M. K., Arceneaux, J. E. L., Hoette, T. M., Strong, R. K., Byers, B. R., and Raymond, K. N. (2006) The anthrax pathogen evades the mammalian immune system through stealth siderophore production. *Proc. Natl. Acad. Sci. U.S.A.* 103, 18499–18503.

(13) Fischbach, M. A., Lin, H., Zhou, L., Abergel, R. J., Liu, D. R., Raymond, K. N., Wanner, B. L., Strong, R. K., Walsh, C. T., Aderem, A., and Smith, K. D. (2006) The pathogen-associated *iroA* gene cluster mediates bacterial evasion of lipocalin 2. *Proc. Natl. Acad. Sci. U.S.A.* 103, 16502–16507.

(14) Gomez, J. E., and McKinney, J. D. (2004) *M. tuberculosis* persistence, latency, and drug tolerance. *Tuberculosis* 84, 29–44.

(15) Rodriguez, G. M., and Smith, I. (2006) Identification of an ABC Transporter Required for Iron Acquisition and Virulence in *Mycobacterium tuberculosis*. *J. Bacteriol.* 188, 424–430.

(16) De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y. Q., and Barry, C. E. (2000) The salicylate-derived mycobactin siderophores of *Mycobacterium tuberculosis* are essential for growth in macrophages. *Proc. Natl. Acad. Sci. U.S.A.* 97, 1252–1257.

(17) Ratledge, C. (2004) Iron, mycobacteria and tuberculosis. *Tuberculosis* 84, 110–130.

(18) Holmes, M. A., Paulsene, W., Xu, J., Ratledge, C., and Strong, R. K. (2005) Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. *Structure* 13, 29–41.

(19) Ratledge, C., and Ewing, M. (1996) The occurrence of carboxymycobactin, the siderophore of pathogenic mycobacteria, as a second extracellular siderophore in *Mycobacterium smegmatis*. *Microbiology* 142, 2207–2212.

(20) Adilakshmi, T., Ayling, P. D., and Ratledge, C. (2000) Mutational analysis of a role for salicylic acid in iron metabolism of *Mycobacterium smegmatis*. *J. Bacteriol.* 182, 264–271.

(21) Lane, S. J., Marshall, P. S., Upton, R. J., and Ratledge, C. (1998) Isolation and characterization of carboxymycobactins as the second extracellular siderophores in *Mycobacterium smegmatis*. *BioMetals* 11, 13–20.

(22) Hoette, T. M., Abergel, R. J., Xu, J., Strong, R. K., and Raymond, K. N. (2008) The role of electrostatics in siderophore recognition by the immunoprotein siderocalin. *J. Am. Chem. Soc.* 130, 17584–17592.

(23) Goetz, D. H., Willie, S. T., Armen, R. S., Bratt, T., Borregaard, N., and Strong, R. K. (2000) Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. *Biochemistry* 39, 1935–1941.

(24) Luo, M. K., Fadeev, E. A., and Groves, J. T. (2005) Mycobactin-mediated iron acquisition within macrophages. *Nat. Chem. Biol.* 1, 149–153.

(25) Kuzmic, P. (1996) Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. *Anal. Biochem.* 237, 260–273.

(26) Frisch, M. J. T. et al. (2004) *Gaussian 03*, Revision C.02, Gaussian, Inc., Wallingford, CT.

(27) Otwinowski, Z., Minor, W. (1997) Methods in Enzymology, in *Macromolecular Crystallography*, Vol. 276, part A (Carter, C.W., Jr. and Sweet, R. M., Eds.) pp 307–326, Academic Press, New York.

(28) Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D60*, 2126–2132.

(29) Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D53*, 240–255.

(30) Collaborative Computational Project, Number 4 (1994) The CCP4 Suite: programs for protein crystallography. *Acta Crystallogr. D50*, 760–763.